Growth factor receptors as targets for drug development: monoclonals beat kinase inhibitors to market, but are they better drugs?

Author：  

Publisher： Informa Healthcare

ISSN： 1354-3776

Source： Expert Opinion on Therapeutic Patents, Vol.9, Iss.4, 1999-04, pp. : 487-489

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Fibroblast Growth Factors/Fibroblast Growth Factor Receptors as Targets for the Development of Anti-Angiogenesis Strategies

By  

Current Pharmaceutical Design, Vol. 13, Iss. 20, 2007-07 ,pp. : 2025-2044

Bentham Science Publishers

Access to resources Recommend Favorite

Orphan Nuclear Receptors as Targets for Drug Development

By Mukherjee Subhajit   Mani Sridhar  

Pharmaceutical Research, Vol. 27, Iss. 8, 2010-08 ,pp. : 1439-1468

Springer Publishing Company

Access to resources Recommend Favorite

Vascular endothelial growth factor tyrosine kinase inhibitors

By  

Expert Opinion on Therapeutic Patents, Vol. 14, Iss. 6, 2004-06 ,pp. : 921-924

Informa Healthcare

Access to resources Recommend Favorite

Clinical Development of Angiogenesis Inhibitors to Vascular Endothelial Growth Factor and Its Receptors as Cancer Therapeutics

By  

Current Cancer Drug Targets, Vol. 2, Iss. 2, 2002-06 ,pp. : 135-156

Bentham Science Publishers

Access to resources Recommend Favorite

Development of Vascular Endothelial Growth Factor Receptor (VEGFR) Kinase Inhibitors as Anti-Angiogenic Agents in Cancer Therapy

By  

Current Medicinal Chemistry, Vol. 11, Iss. 6, 2004-03 ,pp. : 731-745

Bentham Science Publishers

Access to resources Recommend Favorite